Radioactive drug for HER2-positive advanced cancers
Part of Cancer clinical trials.
This trial tests a radioactive drug (lutetium-177) that targets the HER2 protein, which is found on some cancer cells. It's for people with advanced, HER2-positive or HER2-low solid tumors that haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must have the HER2 protein (HER2-positive or HER2-low) and has spread or cannot be removed by surgery, and it has grown despite your last treatment.
- You need to have at least one tumor that can be measured on a scan.
- You must be able to lie still for imaging scans and have no other active serious medical conditions (like uncontrolled heart disease or infections).
- Organ function (kidney, liver, blood counts) must be adequate – your doctor will check with blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET/CT scan to see how a radioactive tracer called Zr-trastuzumab collects in your lung cancer cells. The results will help doctors understand which patients with certain HER2 changes might benefit from HER2-targeted treatments.
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
Hear when a new HER2 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.